Gilenya was supposed to be the multiple sclerosis front runner, taking market share from treatments that have to be injected or infused because it's taken orally. Instead Gilenya looks to be coming up lame in the race.
The Food and Drug Administration slapped a more restrictive label on Gilenya after a patient died last year within a day of starting the multiple sclerosis treatment. The connection between the drug and the death isn't entirely clear, but the FDA doesn't want patients who have had a stroke or other heart issues to take the drug. The agency also recommended increased monitoring of patients after their first dose, including hourly pulse and blood pressure monitoring and an electrocardiogram at the beginning and end of the monitoring period, which lasts at least six hours, but potentially longer if there are heart complications.
The more restrictive label is bad news for Novartis
Risk stratification of Biogen and Elan's
It'll be interesting to see how the safety issues affect Biogen's oral multiple sclerosis drug, BG-12, which is under review at the agency. BG-12 is in a different class than Gilenya, so in theory, the bad news shouldn't really affect BG-12. But Gilenya's troubles could affect doctor's perceptions of new multiple sclerosis drugs in general. The old medications work OK and doctors have a lot of experience with them.
Don't be surprised to see BG-12's sales get off to a slow start as doctors prescribe it just to patients who are needle-phobic. Eventually, though, the drug has good enough efficacy to gain traction once doctors get experience with it.
The multiple sclerosis market is huge, but Fool analysts have found a bigger one. Find out what it is and how to profit from it in our free report: "The Next Trillion-Dollar Revolution." Get your free copy by clicking here.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Teva Pharmaceutical Industries, Novartis, and Pfizer. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.